Last reviewed · How we verify
Tromal (butacetin)
Tromal (generic name: butacetin) is a drug. It is currently in unknown development.
Tromal is thought to work by inhibiting the production of prostaglandins, which are hormone-like substances that cause pain and inflammation.
Tromal (butacetin) is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it is not known whether it is FDA approved or off-patent. The approved indications for Tromal are also unknown. As a small molecule, Tromal is likely to be administered orally, but its pharmacokinetic properties, such as half-life and bioavailability, are not well-documented. Further research is needed to fully understand the clinical profile of Tromal.
At a glance
| Generic name | butacetin |
|---|---|
| Therapeutic area | Pain |
| Phase | unknown |
Mechanism of action
Imagine your body's pain and inflammation response like a fire. Prostaglandins are like the fuel that keeps the fire burning. Tromal works by reducing the amount of fuel available, thereby reducing the pain and inflammation.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tromal CI brief — competitive landscape report
- Tromal updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Tromal
What is Tromal?
How does Tromal work?
What is the generic name of Tromal?
What development phase is Tromal in?
Related
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Pain
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing